Literature DB >> 19301939

Relationship between decrease in ambulatory blood pressure and heart rate variability due to the effects of taking olmesartan medoxomil.

Taiji Furukawa1, Taketo Hatsuno, Yasunari Ueno, Kensuke Nagaoka, Yuji Watari, Takeshi Yamakawa, Toshio Sagawa, Takaaki Isshiki.   

Abstract

UNLABELLED: BACKGROUNDS AND METHODS: A higher degree of clinical efficacy with olmesartan compared with other angiotensin receptor blockers, has been reported by several sources. In this study of 31 examples of cases of essential hypertension, Holter electrocardiogram, ambulatory blood pressure monitoring and pulse wave velocity (PWV) measurements were performed before and after substituting olmesartan 20 mg for candesartan 8 mg antihypertensive drug therapy.
RESULTS: Following the therapeutic change, daily average systolic and diastolic blood pressures were decreased by 6.7 +/- 9.3 mmHg and 3.6 +/- 8.3 mmHg, respectively, with olmesartan 20 mg; PWV was also significantly decreased. Holter electrocardiogram heart rate variability spectral analysis demonstrated that none of the very low frequency (VLF), high frequency (HF) and low frequency (LF)/HF components were significantly altered. However, a significant correlation was observed between the LF/HF component and blood pressure difference, when blood pressure and heart rate variability components in each individual case were studied.
CONCLUSION: This study shows that olmesartan has a stronger antihypertensive effect in comparison to candesartan, and does not generate reflex sympathoexcitatory activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19301939     DOI: 10.2165/00044011-200929040-00004

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  11 in total

1.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Authors:  J N Cohn; G Tognoni
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Aortic stiffness is an independent predictor of fatal stroke in essential hypertension.

Authors:  Stéphane Laurent; Sandrine Katsahian; Céline Fassot; Anne-Isabelle Tropeano; Isabelle Gautier; Brigitte Laloux; Pierre Boutouyrie
Journal:  Stroke       Date:  2003-04-03       Impact factor: 7.914

3.  Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study.

Authors:  Pierre Boutouyrie; Anne Isabelle Tropeano; Roland Asmar; Isabelle Gautier; Athanase Benetos; Patrick Lacolley; Stéphane Laurent
Journal:  Hypertension       Date:  2002-01       Impact factor: 10.190

4.  Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives.

Authors:  K J Ball; P A Williams; K O Stumpe
Journal:  J Hypertens Suppl       Date:  2001-06

5.  Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.

Authors:  Hans R Brunner; Kikuo Arakawa
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

6.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.

Authors:  C D Furberg; B M Psaty; J V Meyer
Journal:  Circulation       Date:  1995-09-01       Impact factor: 29.690

Review 7.  Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.

Authors:  Klaus O Stumpe
Journal:  Clin Ther       Date:  2004       Impact factor: 3.393

8.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Authors:  Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Salim Yusuf; Stuart Pocock
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

9.  Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.

Authors:  S Oparil; D Williams; S G Chrysant; T C Marbury; J Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Sep-Oct       Impact factor: 3.738

Review 10.  Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies.

Authors:  C Ventika S Ram
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-10       Impact factor: 3.738

View more
  2 in total

1.  Effects of percutaneous coronary intervention on the ambulatory blood pressure of patients with hypertension and coronary heart disease.

Authors:  Jing Yang; Xuming Yang; Wei Liu; Tingting Cao
Journal:  Ir J Med Sci       Date:  2014-09-17       Impact factor: 1.568

2.  Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.

Authors:  Hiroyuki Daikuhara; Kensaku Fukunaga; Tomie Ohshima
Journal:  Drug Des Devel Ther       Date:  2014-02-17       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.